Skinbiotherapeutics Share Discussion Threads

[ileeman] 21/2/2019 16:14

Added a few more, seems it failed to smash above 20p on the first attempt but positive it will soon enough.

Cornerstone investor is a big give away to what is about to happen.

[rafboy] 21/2/2019 14:12

Yes, I have had a few more here and at OPTI today.

[2350220] 21/2/2019 09:56

Just added a bit more to my September Spreadbets.

[someuwin] 20/2/2019 13:02

...Yup - but it'll be 4 bagger if it gets back to where it was.

[riskybusiness1] 20/2/2019 12:26

Nothing particularly novel about that company hence why it has halved & then halved again since listing same day as SBTX two years ago

[manc10] 20/2/2019 11:16

this is a sbtx thread

[someuwin] 20/2/2019 09:09

O/T The other medical skin company (LSE:SKIN) looks very interesting now.

[ileeman] 20/2/2019 08:48

Dropped but not letting you buy FWIW

[ileeman] 19/2/2019 17:23

Major breakout, back testing 19pish...targets towards 30p.


free stock charts from uk.advfn.com

[2350220] 19/2/2019 14:08

Mmm, this chart looks distinctly like Batman!!
John

[parob] 19/2/2019 09:10

Yep and the inverse head & shoulders playing out perfectly...

[rafboy] 19/2/2019 09:04

Well the share price is rising so no complaints here LOL.

[ileeman] 19/2/2019 08:34

Not sure what is going on recently but fwiw they are not allowing buyers and are bidding for stock over 20p.

[shrewdmole] 19/2/2019 02:03

Guys don’t be greedy.

We have one of the shrewdest people on aim in soh behind this and Opti and he will not dilute his interest without good reason.

Unlike many aim ceo it’s not to guarantee his wages.

Most the people here are scientists and they are buzzing. Let’s just get the right ceo in to maximise the revenue and wat h this baby grow.

[jamesrs1] 18/2/2019 19:47

Maybe another rns in the morning ?

[owenmo] 18/2/2019 19:46

Decent of you Anders to be so helpful and so specific. I even put United v Chelsea on pause to engage. Thanks. My uncertainty was centred in wondering if "another company" was friend or foe; now I know.

[dire cons] 18/2/2019 19:22

Specially for OwenMo

Tuesday 03 April, 2018

SkinBioTherapeuticsSBTX signs MTA with global consumer goods company

RNS Number : 4957J

SkinBioTherapeutics PLC

03 April 2018

 

SkinBioTherapeutics plc

 

SkinBioTherapeutics signs MTA (material transfer agreement) with global consumer goods company

 

Manchester, UK - 03 April 2018 - SkinBioTherapeutics plc (AIM: SBTX,  the "Company"), a life science company focused on skin health, announces the signing of an MTA relating to its proprietary SkinBiotix® technology with a major, global consumer goods company.

The Company has been speaking to a range of commercial partners interested in evaluating its SkinBiotix® technology ahead of its human studies which are scheduled to commence later this year.

Having shared the initial pre-clinical data with a number of interested parties, one potential partner to date has progressed to an MTA, granting it access to the SkinBiotix® technology. An MTA is a standard agreement governing the transfer of material between parties enabling the recipient to assess the technology and, where the outcome is successful, can be a precursor to future commercial discussions.

The MTA provides for SkinBioTherapeutics to share a sample of its material against which the third party will conduct its own in-house assessment. Whilst at this stage there can be no certainty that discussions will progress further than the initial sharing of the technology, the Company is encouraged by the level of interest that has been shown in its pre-clinical data.

The Company is initially targeting cosmetic skin care and in this market SkinBioTherapeutics' skin microbiome technology is unusual in that its properties are supported by scientific data. These demonstrate its ability to improve the skin barrier, offer protection from infection and enhance skin repair. These characteristics support potential opportunities for the Company in cosmetics, anti-infectives and dermatological indications (e.g. eczema).

 

Most recently, the Company reported good results in a variety of toxicity studies and the development of its formulation as a gel, cream and lotion which will be tested to determine the best concentration and application for its humans studies. 

 

Dr Cath O'Neill, CEO of SkinBioTherapeutics, commented:

"Whilst these are early discussions, we are encouraged that a company of this calibre wants to look at our technology more closely through an MTA.  Even at this early stage of its development, we are pleased to see that SkinBiotix® is starting to generate a buzz in the skin care industry."

[owenmo] 18/2/2019 19:13

So Seneca secured a bargain discounted deal @ 16p. And sure the world an his wife could have bought on the market @ 13p. six weeks ago!

[owenmo] 18/2/2019 19:05

Anders, slow on up-take; sounds like there are good tidings of sorts in your missive. For guys like me could you spell it out with a little more detail? Ta.

[anderson3] 18/2/2019 18:56

Need to remember a company started evaluating this technology about 7 months ago, it was RNS’d. Probably had some good feedback

[riskybusiness1] 18/2/2019 16:39

From Interim 'In addition, the Company is assessing how it can apply its microbiome and dermatological expertise to other skin conditions, for example psoriasis where the Company is in discussions with a third party for a potential joint development agreement.'JD could involve extra funding to fast track high value medical device route hence placing. Wouldn't be surprised to see a few decent announcements on the back of today. If they announce a heavy hitter Ceo soon & commercial deals this will really start to come to life.

[ileeman] 18/2/2019 16:35

Could not buy at 20.5p went straight to NT.

No way the shareholder today who bought the fund raise could buy that amount open market without significantly increasing the price, so makes you wonder why they want to increase so badly....